CEO of Arterial Remodeling Technologies (“ART”) Will Update the Industry Today on the State of Bioresorbable Stents at the

PARIS--(BUSINESS WIRE)-- Arterial Remodeling Technologies (“ART”) announced today that its CEO, Machiel van der Leest, has been invited to present an update on the state of bioresorbable stents during today’s 23rd annual meeting of the ‘ESB’ (European Society of Biomaterials), at Tampere (Finland) University of Technology.

Prior to joining ART, Mr. van der Leest was a co-founder and Chief Technology Officer of Minvasys. During his career he has developed and successfully introduced 15 Class III medical devices, which required pre-market approval and a scientific review to ensure safety and effectiveness.

“This is a very exciting time in the development of bioresorbable stents,” said Mr. van der Leest. “Over time, these stents leave behind only the healed natural vessel, thereby permitting renewal of vasoreactivity along with the probability of vessel remodeling. Equally important to note is that late stent thrombosis is improbable because the stent has bioresorbed, and therefore extended antiplatelet therapy is unnecessary with this approach.”

About Arterial Remodeling Technologies (“ART”)

Arterial Remodeling Technologies (“ART”) is developing bioresorbable coronary polymer stents that promote the natural remodeling of an injured artery after angioplasty. The Company’s technology is based on intellectual property originating from three esteemed institutions: the Cleveland Clinic; the French national research institute, CNRS (Centre National de Recherche Scientifique), Montpellier, France; and, Descartes University, Paris.



CONTACT:

Ronald Trahan Associates Inc.
Ronald Trahan, APR, 508-359-4005, x108

KEYWORDS:   United States  Europe  North America  France

INDUSTRY KEYWORDS:   Health  Cardiology  Medical Devices

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.